Endothelial cells for treatment of gastrointestinal fistula
AssigneesAngiocrine Bioscience, Inc., Cornell University
InventorsPaul William Finnegan, Jeffrey W. Milsom
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of endothelial cells for the treatment of gastrointestinal fistula and provides compositions and methods relating thereto. In some aspects of the present invention the endothelial cells are E4ORF1+ endothelial cells, such as E4ORF1+ human umbilical vein endothelial cells.
Claims32
A method of treating a GI fistula in a human subject in need thereof, the method comprising administering to a human subject with a GI fistula a composition comprising E4ORF1+ human umbilical vein endothelial cells (E4ORF1+ HUVECs), wherein:
- (a) from about 5×106 to about 200×106 total E4ORF1+ HUVECs, or (b) from about 5×106 to about 120×106 E4ORF1+ HUVECs per cm of fistula length, are administered to the subject by local administration at the site of the GI fistula, thereby treating the GI fistula in the subject.
A method of treating a GI fistula in a human subject in need thereof, the method comprising administering an effective amount of a composition comprising E4ORF1+ HUVECs to a human subject with a GI fistula by local administration at the site of the GI fistula, wherein the subject is not treated by fistulotomy, thereby treating the GI fistula in the subject.
The method of any of the preceding claims, wherein the administration of the E4ORF1+ HUVECs comprises depositing the E4ORF1+ HUVECs along the length of the GI fistula.
The method of any of the preceding claims, wherein curettage of the GI fistula is performed prior to administration of the E4ORF1+ HUVECs.
The method of any of the preceding claims, further comprising surgically closing the internal opening of the GI fistula.
The method of any of the preceding claims, further comprising surgically closing the internal opening of the GI fistula using sutures.
The method of any of the preceding claims, comprising repeating the administration of E4ORF1+ HUVECs to the subject multiple times, wherein the time interval between administrations is from about 2 weeks to about 12 weeks.
The method of any one of the preceding claims, where the GI fistula is an enterocutaneous fistula.
The method of any one of the preceding claims, where the GI fistula is an entero-enteral fistula.
The method of any one of the preceding claims, where the GI fistula is an anal fistula, an anorectal fistula, an anovaginal fistula, an appendiceal fistula, a biliary fistula, a cecal fistula, a colonic fistula, a colorectal fistula, a colovesical fistula, a duodenal fistula, a duodeno-colic fistula, an enterovesical fistula, an esophageal fistula, a gallbladder fistula, a gastric fistula, a gastrocolic fistula, a gastrojejunocolic fistula, an ileal fistula, a jejunal fistula, an oral fistula, a pancreatic fistula, a rectal fistula, a rectovaginal fistula, or a salivary gland fistula.
The method of any one of the preceding claims, where the GI fistula is an anal fistula.
The method of any of the preceding claims, wherein the composition comprises E4ORF1+ HUVECs and one or more excipients suitable for administration to a human subject selected from the group consisting of diluents, buffers, salts, polysaccharides, proteins, and preservatives.
The method of any of the preceding claims, wherein the composition is administered locally using a needle.
The method of any of the preceding claims, wherein the composition is administered locally under imaging guidance.
Dependencies are inferred from the claim text.